| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/18/2009 | US7575742 Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
| 08/18/2009 | US7575740 Applying to the tissue formulation comprising first precursor component second precursor component comprises electrophilic component which crosslink at physiological temperatures over a period of time following application |
| 08/18/2009 | US7575577 Devices and methods for the restoration of a spinal disc |
| 08/18/2009 | US7575547 Cardiac support device with anti-fibrosis coating |
| 08/18/2009 | CA2577233C Pharmaceutical composition containing angiotensin ii antagonist |
| 08/18/2009 | CA2429270C Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 08/18/2009 | CA2429133C Novel imidazole derivatives, production method thereof and use thereof |
| 08/18/2009 | CA2377254C Non-malignant disease treatment with ras antagonists |
| 08/18/2009 | CA2335250C Temperature-sensitive liposomal formulation |
| 08/18/2009 | CA2288215C Use of immunomodulating agents |
| 08/18/2009 | CA2224008C The treatment of hiv and other viral infections using combinatorial therapy |
| 08/13/2009 | WO2009099563A2 Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease |
| 08/13/2009 | WO2009099316A1 Use of lipid-rich nutrition for the treatment of post-operative ileus |
| 08/13/2009 | WO2009097692A1 Biomarkers for head-and-neck cancers and precancers |
| 08/13/2009 | WO2009097691A1 USE OF P27kip1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE |
| 08/13/2009 | WO2009097688A1 Compositions and methods for alleviating depression or improving cognition |
| 08/13/2009 | WO2009097670A1 Combination of immunomodulator and anti-pathogenic agent |
| 08/13/2009 | WO2009072132A3 Beta glycolipids for the treatment of calcification related degenerative disorders |
| 08/13/2009 | WO2009071903A3 Composition comprising a chondroitin sulphate proteoglycan inhibitory agent and an anti-inflammatory agent |
| 08/13/2009 | WO2009027056A3 Antioxidant and paramagnetic heparin-nitroxide derivatives |
| 08/13/2009 | WO2008145281A3 Formulations containing triazinones and iron |
| 08/13/2009 | WO2008143880A8 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury |
| 08/13/2009 | WO2008121028A3 Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer |
| 08/13/2009 | WO2008108958A8 Benzimidazole derivatives and methods of use thereof |
| 08/13/2009 | WO2008066854A3 Methods and compositions for inducing apoptosis in cancer cells |
| 08/13/2009 | US20090204204 Drug/Drug Deliver Systems For The Prevention And Treatment Of Vascular Disease |
| 08/13/2009 | US20090204062 Method for administering a therapeutic agent into tissue |
| 08/13/2009 | US20090203906 4-[((4-carboxybutyl){2-[2-({4-[2-(4-hydroxyphenyl)ethyl]benzyl}oxy)phenyl]-ethyl}amino)methyl]benzoic acid, which stimulate soluble guanylate cyclase via a novel mechanism of action, used for the treatment of cardiovascular disorders and fibrotic disorders |
| 08/13/2009 | US20090203798 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol |
| 08/13/2009 | US20090203782 Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders |
| 08/13/2009 | US20090203770 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING Bcl-2 FAMILY MEMBER PROTEINS |
| 08/13/2009 | US20090203767 Inhibition stat-1 |
| 08/13/2009 | US20090203722 Novel compositions and methods for enhancing potency or reducing adverse side effects of opiold agonists |
| 08/13/2009 | US20090203720 Methods for inhibiting cell growth |
| 08/13/2009 | US20090203719 Enhancing treatment of mdr cancer with adenosine a3 antagonists |
| 08/13/2009 | US20090203655 Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| 08/13/2009 | US20090203633 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 08/13/2009 | US20090203609 Use of IL-1 inhibitors for treating IL-1 mediated diseases |
| 08/13/2009 | US20090203122 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 08/13/2009 | US20090203114 Novel methods and interferon deficient substrates for the propagation of viruses |
| 08/13/2009 | US20090203044 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 08/13/2009 | US20090202577 CASB618 Polynucleotides and Polypeptides and Their Use |
| 08/13/2009 | US20090202575 Immunostimulatory nucleic acid molecules |
| 08/13/2009 | US20090202571 Bioreductively-activated prodrugs |
| 08/13/2009 | US20090202561 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 08/13/2009 | US20090202541 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 08/13/2009 | US20090202489 Adenoviruses mutated in the va genes for cancer treatment |
| 08/13/2009 | CA2714972A1 Use of p27kip1 for the prevention and treatment of heart failure |
| 08/13/2009 | CA2713850A1 Biomarkers for head-and-neck cancers and precancers |
| 08/13/2009 | CA2712800A1 Compositions and methods for alleviating depression or improving cognition |
| 08/13/2009 | CA2712593A1 Methods for treating a condition characterized by dysfunction in protein homeostasis |
| 08/12/2009 | EP2088158A2 Monoclonal antibody against the CCR5 chemokine receptor |
| 08/12/2009 | EP2087908A1 Antibodies to opgl |
| 08/12/2009 | EP2087894A1 Formulations comprising PIECID and RESVERATROL able to prevent and inhibit lipid peroxidation |
| 08/12/2009 | EP2087892A2 (S,S) reboxetine for treating age associated learning and mental disorders |
| 08/12/2009 | EP2087891A2 Pharmaceutical compositions for treating lymphoma |
| 08/12/2009 | EP2087888A1 Adenosine a1 receptor antagonists for the treatment of alkalosis |
| 08/12/2009 | EP2086644A2 Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| 08/12/2009 | EP2086641A2 Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders |
| 08/12/2009 | EP2086585A2 Composition for a pharmaceutical treatment based on triethyl citrate and adapalene |
| 08/12/2009 | EP2086541A2 Compositions for reducing nicotine withdrawal symptoms and/or tobacco usage |
| 08/12/2009 | EP2086538A2 Combination therapies for treating alzheimer's disease using i.a. dimebon and dolepezil |
| 08/12/2009 | EP2086535A2 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats |
| 08/12/2009 | EP2086511A2 Polymer-based antimicrobial agents, methods of making said agents, and products and applications using said agents |
| 08/12/2009 | EP2086320A2 Compositions and methods for treating jellyfish stings |
| 08/12/2009 | EP1949906A4 Agent for correcting stress-inducing neuro-mediator, neuro- endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 08/12/2009 | EP1913155A4 Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
| 08/12/2009 | EP1904077B1 Modulating responsiveness to steroids |
| 08/12/2009 | EP1601346B1 Method for producing a pharmaceutical composition in the form of fibrate-containing tablets and tablets produced by said method |
| 08/12/2009 | EP1514116B1 Oxaliplatin anti-resistance method |
| 08/12/2009 | EP1503756B1 Epothilone derivative for the treatment of hepatoma and other cancer diseases |
| 08/12/2009 | EP1423105B9 Combinations of dmxaa and other anti-cancer agents |
| 08/12/2009 | EP1416048B1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 08/12/2009 | EP1392328B1 Medicament for protection in radiotherapy |
| 08/12/2009 | EP1347753B3 Topical composition and method for treating urinary stress incontinence |
| 08/12/2009 | EP1343760B1 Muscarinic antagonists |
| 08/12/2009 | EP1290227B1 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 08/12/2009 | EP1259608B1 Modified fluorescent proteins |
| 08/12/2009 | EP1198589B9 Tenascin-c nucleic acid ligands |
| 08/12/2009 | EP1149111B1 Method and composition for angiogenesis inhibition |
| 08/12/2009 | EP1127944B9 Methods for screening compounds inhibiting inflammatory cytokine production |
| 08/12/2009 | EP0898580B9 Methods and means for inhibition of cdk4 activity |
| 08/12/2009 | CN101506145A Aminoalcohol derivative and immunosuppressant containing the same as active ingredient |
| 08/12/2009 | CN101505797A Pharmaceutical compositions for the treatment of fungal infections |
| 08/12/2009 | CN101505796A Soft tissue repair and regeneration using stem cell products |
| 08/12/2009 | CN101505788A Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 08/12/2009 | CN101505760A Combinations comprising staurosprorines |
| 08/12/2009 | CN101505758A Pharmaceutical containing thiazole derivative as active ingredient |
| 08/12/2009 | CN101505755A Agent for overcoming resistance to anti-cancer agent |
| 08/12/2009 | CN101505749A Use of PKC inhibitors in particular indolylmaleimide derivatives in ocular diseases |
| 08/12/2009 | CN101505725A Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility |
| 08/12/2009 | CN101502653A Medicament composition for preventing or treating Streptococcus suis disease |
| 08/12/2009 | CN101502509A Medicament for repairing mesothelium, endothelium and epidermal tissue, as well as preventing adhesions and obstruction, and preparation method |
| 08/12/2009 | CN101502500A Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 08/12/2009 | CN101502484A Glucocorticosteroid and chemotherapy medicament carried by anticancer sustained-release agent |
| 08/12/2009 | CN100526309C Dimeric compounds and their use as anti-viral agents |
| 08/12/2009 | CN100525830C Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and prod |
| 08/12/2009 | CN100525763C Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| 08/12/2009 | CN100525761C Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders |
| 08/12/2009 | CN100525631C Non invasive measurements of chemical substances |